Brion W Murray

List of Publications by Year
in descending order

60 papers	9,851 citations	94433 37 h-index	133252 59 g-index
106 all docs	106 docs citations	106 times ranked	13194 citing authors

#	Article	IF	Citations
1	SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13681-13686.	7.1	2,350
2	IKK-1 and IKK-2: Cytokine-Activated IÎºB Kinases Essential for NF-ÎºB Activation. Science, 1997, 278, 860-866.	12.6	1,995
3	Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research, 2008, 14, 7272-7283.	7.0	555
4	Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19. Journal of Medicinal Chemistry, 2020, 63, 12725-12747.	6.4	371
5	Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18281-18289.	7.1	361
6	IÎºB Kinase (IKK)-Associated Protein 1, a Common Component of the Heterogeneous IKK Complex. Molecular and Cellular Biology, 1999, 19, 1526-1538.	2.3	320
7	Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance. Molecular Cancer Therapeutics, 2016, 15, 2273-2281.	4.1	294
8	Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9446-9451.	7.1	262
9	PAK signaling in oncogenesis. Oncogene, 2009, 28, 2545-2555.	5.9	219
10	Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 173-178.	7.1	217
11	Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature, 2015, 519, 102-105.	27.8	207
12	JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. Genes and Development, 1998, 12, 3369-3381.	5.9	181
13	p38-2, a Novel Mitogen-activated Protein Kinase with Distinct Properties. Journal of Biological Chemistry, 1997, 272, 19509-19517.	3.4	157
14	Mechanism of Human Î±-1,3-Fucosyltransferase V:â€‰ Glycosidic Cleavage Occurs Prior to Nucleophilic Attack. Biochemistry, 1997, 36, 823-831.	2.5	128
15	Synergistic Inhibition of Human Î±-1,3-Fucosyltransferase V. Journal of the American Chemical Society, 1996, 118, 7653-7662.	13.7	126
16	Mechanism and Specificity of Human Î±-1,3-Fucosyltransferase Vâ€. Biochemistry, 1996, 35, 11183-11195.	2.5	121
17	Chemo-enzymatic synthesis of fluorinated sugar nucleotide: useful mechanistic Probes for glycosyltransferases. Bioorganic and Medicinal Chemistry, 2000, 8, 1937-1946.	3.0	120
18	Protein kinase biochemistry and drug discovery. Bioorganic Chemistry, 2011, 39, 192-210.	4.1	118

#	Article	IF	Citations
19	Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate. Journal of Medicinal Chemistry, 2017, 60, 9617-9629.	6.4	118
20	Enzymatic Characterization of c-Met Receptor Tyrosine Kinase Oncogenic Mutants and Kinetic Studies with Aminopyridine and Triazolopyrazine Inhibitors. Biochemistry, 2009, 48, 5339-5349.	2.5	92
21	Structure-based design of novel human Pin1 inhibitors (II). Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2210-2214.	2.2	88
22	Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer. Journal of Medicinal Chemistry, 2012, 55, 8091-8109.	6.4	88
23	Recent progress on third generation covalent EGFR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1861-1868.	2.2	87
24	Structure-based design of novel human Pin1 inhibitors (I). Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5613-5616.	2.2	85
25	Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)m (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. Journal of Medicinal Chemistry, 2016, 59, 2005-2024.	6.4	77
26	Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor. Cancer Cell, 2021, 39, 1404-1421.e11.	16.8	71
27	Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrro (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. Journal of Medicinal Chemistry, 2017, 60, 3002-3019.	6.4	68
28	Molecular properties of pyruvate formate-lyase activating enzyme. Biochemistry, 1993, 32, 14102-14110.	2.5	67
29	Cyclic Amidine Sugars as Transition-State Analogue Inhibitors of Glycosidases: Potent Competitive Inhibitors of Mannosidases. Journal of the American Chemical Society, 2004, 126, 1971-1979.	13.7	57
30	Protein redox chemistry: post-translational cysteine modifications that regulate signal transduction and drug pharmacology. Frontiers in Pharmacology, 2014, 5, 224.	3.5	55
31	Cyclic Guanidino-Sugars with Low pKaas Transition-State Analog Inhibitors of Glycosidases:Â Neutral Instead of Charged Species Are the Active Forms. Journal of the American Chemical Society, 1996, 118, 4227-4234.	13.7	54
32	Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 2021, 64, 9056-9077.	6.4	54
33	A chemoenzymatic synthesis of UDP-(2-deoxy-2-fluoro)galactose and evaluation of its interaction with galactosyltransferase. Bioorganic and Medicinal Chemistry, 1997, 5, 497-500.	3.0	51
34	Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 2104-2115.	4.1	51
35	TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations. Molecular Cancer Therapeutics, 2021, 20, 1499-1507.	4.1	50
36	Discovery of Pyrroloaminopyrazoles as Novel PAK Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 4728-4739.	6.4	48

#	Article	IF	Citations
37	Characterizing the Effects of the Juxtamembrane Domain on Vascular Endothelial Growth Factor Receptor-2 Enzymatic Activity, Autophosphorylation, and Inhibition by Axitinib. Biochemistry, 2009, 48, 7019-7031.	2.5	45
38	Steady-State and Pre-Steady-State Kinetic Evaluation of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL^{pro} Cysteine Protease:â€‰ Development of an Ion-Pair Model for Catalysis. Biochemistry, 2008, 47, 2617-2630.	2.5	39
39	Mechanistic Effects of Autophosphorylation on Receptor Tyrosine Kinase Catalysis:Â Enzymatic Characterization of Tie2 and Phospho-Tie2. Biochemistry, 2001, 40, 10243-10253.	2.5	37
40	Why Is CMP-Ketodeoxyoctonate Highly Unstable?. Biochemistry, 1997, 36, 780-785.	2.5	35
41	Structure-based design of novel human Pin1 inhibitors (III): Optimizing affinity beyond the phosphate recognition pocket. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 4187-4191.	2.2	35
42	The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. Journal of Biological Chemistry, 2017, 292, 15705-15716.	3.4	35
43	Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations. Molecular Cancer Therapeutics, 2021, 20, 2446-2456.	4.1	35
44	Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Frontiers in Pharmacology, 2013, 4, 35.	3.5	32
45	Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Frontiers in Pharmacology, 2013, 4, 22.	3.5	30
46	Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. PLoS ONE, 2015, 10, e0138616.	2.5	30
47	Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling. Cell Reports, 2020, 30, 1935-1950.e8.	6.4	28
48	Durability of Kinase-Directed Therapiesâ€”A Network Perspective on Response and Resistance. Molecular Cancer Therapeutics, 2015, 14, 1975-1984.	4.1	22
49	A simple and efficient maleimide-based approach for peptide extension with a cysteine-containing peptide phage library. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5680-5683.	2.2	17
50	Development of a Nonradioactive, Time-Resolved Fluorescence Assay for the Measurement of Jun N-Terminal Kinase Activity. Journal of Biomolecular Screening, 1997, 2, 213-223.	2.6	15
51	An algebraic model for the kinetics of covalent enzyme inhibition at low substrate concentrations. Analytical Biochemistry, 2015, 484, 82-90.	2.4	13
52	Identification and characterization of a novel and functional murine Pin1 isoform. Biochemical and Biophysical Research Communications, 2007, 359, 529-535.	2.1	10
53	Analysis of pharmacologic inhibitors of Jun N-terminal kinases. Methods in Enzymology, 2001, 332, 432-452.	1.0	7
54	Analysis of Cysteine Redox Post-Translational Modifications in Cell Biology and Drug Pharmacology. Methods in Molecular Biology, 2017, 1558, 191-212.	0.9	6

#	Article	IF	Citations
55	Genomic profiling and treatment of HER2+, ER+, PgR+ â€œtriple positiveâ€•breast cancer: A case report and literature review. Cancer Treatment and Research Communications, 2016, 9, 27-31.	1.7	5
56	Substrate-Specific Conformational Regulation of the Receptor Tyrosine Kinase VEGFR2 Catalytic Domain. ACS Chemical Biology, 2013, 8, 978-986.	3.4	4
57	Maleimide-Based Method for Elaboration of Cysteine-Containing Peptide Phage Libraries. Methods in Molecular Biology, 2015, 1248, 267-276.	0.9	3
58	Proteinâ€“inhibitor complexes analyzed by alkaline capillary LCâ€“MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 825, 176-185.	2.3	2
59	Countering Breast Cancer's Counterpunch. Molecular Cancer Therapeutics, 2019, 18, 1682-1683.	4.1	0
60	Inhibitors of the MAPK pathway. , 2000, , 165-191.		0